Our findings suggested that IL-6 or IL-8 can be utilized as independent predictors of efficacy and complement tumor markers CEA, CA50, CA199, and CA724 in predicting the effectiveness of immunotherapy in AGC patients. Here, IL6 is linked to neoplasm.